Minnnesota Bioscience Jobs

Job Information

Pfizer, Inc. Director, Health Evidence and Outcomes Research, Pipeline and BD, Oncology and Vaccine in Minneapolis, Minnesota

The Health Economics and Outcomes Research (HEOR) Director, will serve as a principal HEOR strategist for early development oncology and vaccines. In collaboration with the asset development team, the Senior Director will formulate HEOR strategy and conduct/oversee evidence generation activities, in particular, real world data (RWD) studies, to support the asset in the early pipeline phase and prepare for phase 3. The Director is responsible for the overall quality, scientific and technical excellence of HEOR deliverables. The execution of this position will require the ability to develop economic models for cost-effectiveness and budget impact, particularly for broad population-based patient targets (i.e. vaccines) in addition to integrate / recommend patient-reported outcomes data in clinical trial protocols in addition to close collaboration with Clinical, Commercial, PHI Oncology and Vaccines Business Unit Strategists, and Medical. This position will function with a 'One Patient and Health Impact' mindset and will work in a closely aligned fashion with the Oncology PHI team members to ensure there is a single and coordinated view on strategy and delivery. This position reports to the Patient and Health Impact Early Clinical and Business Development Oncology and Vaccines Integrated Team Lead. ROLE RESPONSIBILITIES Independently lead HEOR strategy development and implementation to support patient-centric and payer-optimized development scenarios including prioritization of high value programs. Develops evidence generation activities, such as: RWD studies of comparative effectiveness and cost; design and implementation of clinical trials with HEOR components; and early economic models, aligned with the overall product strategy. Lead development of early economic modeling for population selection and early pricing. Able to influence and shape the clinical development plan utilizing individual depth of knowledge and experience in value evidence generation and reimbursement. Represent Pfizer's interests in high level interactions with influential bodies (affiliates, international health administration bodies, advocacy groups, specialty associations, etc.). Provide relevant input into selection of patient population and comparators within clinical trials to enable demonstration of robust incremental clinical value over standard of care that can facilitate optimal patient access. Develop and propose the selection, related analyses, interpretation and communication of Patient Reported Outcomes (PRO) measures as appropriate for assigned clinical trials, registries, and prospective real world studies. Collaborate with local affiliates to identify the best study design in preparation of Phase 3. Lead appropriate data dissemination plans and communicate in a timely manner evidence generated to various stakeholders via publications and conference presentations. QUALIFICATIONS Candidate demonstrates a breadth of diverse leadership experiences and capabilities including: the ability to influence and collaborate with peers, develop and coach others, oversee and guide the work of other colleagues to achieve meaningful outcomes and create business impact. PhD in relevant discipline (health services research, epidemiology, health economics, psychology, etc.) with 7+ years of work experience in the conduct of outcomes research to evaluate health care interventions. Or a Master's degree in a relevant discipline with 8+ years. Or a Bachelor's degree in a relevant discipline with 10+ years of experience - with pharmaceutical research in several therapeutic areas evaluating health care interventions with 5+ years of that research experience conducting health economics, health related quality of life and epidemiology studies in the pharmaceutical industry. Has substantial technical knowledge and extensive experience of planning and delivering HEOR programs, particularly RWD studies and cost-effectiveness modeling, across multiple